All In Biotech

Drug Trial Radar · NCT06592274

A Phase 2 Study of HB0017 in Psoriasis Patients

A Multicenter, Randomized, Double-blind Phase 2 Clinical Study Evaluating the Efficacy and Safety of Different Administration Regimens of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

206

Actual

Start

Sep 30, 2024

Primary completion

Apr 30, 2025

Study completion Apr 10, 2026

Sponsor

Lead sponsor
Huabo Biopharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects

Conditions

  • Psoriasis (PsO)

Interventions

  • HB0017Biological

    300mg Q12W

  • HB0017Biological

    300mg Q8W

  • HB0017Biological

    150mg Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving PASI 90 responseTime frame: Week 12
  2. Proportion of subjects achieving sPGA 0/1Time frame: Week 12

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • Ningbo Second Hospital

    Ningbo, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Southern Medical University Dermatology Hospital

    Guangzhou, Guangdong, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Wuxi Second People's Hospital

    Wuxi, Jiangsu, China

  • Jiangsu University Affiliated Hospital

    Zhenjiang, Jiangsu, China

  • Jilin University Second Hospital

    Changchun, Jilin, China

  • Shandong First Medical University Affiliated Dermatology Hospital

    Jinan, Shandong, China

  • Jining First People's Hospital

    Jining, Shandong, China

  • Xingtai People's Hospital

    Xingtai, Shandong, China

  • Shanxi Medical University Second Hospital

    Taiyuan, Shanxi, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Chongqing Traditional Chinese Medicine Hospital

    Chongqing, Sichuan, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Jiaxing First Hospital

    Jiaxing, Zhejiang, China

  • Wenzhou Medical University Affiliated First Hospital

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.